tradingkey.logo

Editas Medicine Inc <EDIT.OQ> expected to post a loss of 36 cents a share - Earnings Preview

ReutersFeb 24, 2025 1:53 PM
  • Editas Medicine Inc EDIT.OQ EDIT.O is expected to show a fall in quarterly revenue when it reports results on February 26 (estimated) for the period ending December 31 2024

  • The Cambridge Massachusetts-based company is expected to report a 46.3% decrease in revenue to $32.23 million from $60.05 million a year ago, according to the mean estimate from 12 analysts, based on LSEG data.

  • ​LSEG's mean analyst estimate for Editas Medicine Inc is for a loss of 36 cents per share.

  • The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 4 "strong buy" or "buy," 9 "hold" and 2 "sell" or "strong sell."

  • The mean earnings estimate of analysts was unchanged in the last three months. ​

  • Wall Street's median 12-month price target for Editas Medicine Inc is $3.50​, above​ its last closing price of $1.92. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING

STARMINESMARTESTIMATE®

LSEG IBES ESTIMATE

ACTUAL

BEAT, MET, MISSED

SURPRISE %

Sep. 30 2024

-0.72

-0.75

-0.75

Met

-0.4

Jun. 30 2024

-0.73

-0.70

-0.82

Missed

-16.6

Mar. 31 2024

-0.66

-0.66

-0.76

Missed

-14.3​

Dec. 31 2023

-0.60

-0.54

-0.23

Beat

57.6

​​Sep. 30 2023

-0.56

-0.57

-0.55

Beat

3.2

Jun. 30 2023

-0.76

-0.76

-0.56

Beat

26.6​

Mar. 31 2023

-0.78

-0.78

-0.71

Beat

9.4

Dec. 31 2022

-0.80

-0.80

-0.88

Missed

-9.7

This summary was machine generated February 24 at 13:53 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI